Literature DB >> 34277333

Saliva sample and SARS-CoV-2 detection: More complexities than clarity.

Sachin C Sarode1, Gargi S Sarode1.   

Abstract

Entities:  

Year:  2021        PMID: 34277333      PMCID: PMC8276566          DOI: 10.1016/j.jobcr.2021.07.002

Source DB:  PubMed          Journal:  J Oral Biol Craniofac Res        ISSN: 2212-4268


× No keyword cloud information.
In recent time, saliva has been extensively investigated for its potential as a diagnostic aid for detection of SARS-CoV-2 infection. The source of virus in saliva is still controversial and researchers claim that the virus particles possibly come from the respiratory system and infect salivary glands. A significant number of studies reported statistically high sensitivity and specificity of the saliva-based diagnosis of SARS-CoV-2 infection. Proposed advantages are highly encouraging such as less-invasive, convenient, associated ease of self-collection and minimal risk of cross-infection. Due to the presence of justifiable advantages over the nasopharyngeal swab, saliva-based SARS-CoV-2 testing has been projected as a gold standard methodology, challenging the conventional nasopharyngeal swab testing. Recently conducted research by Pasomsub et al. reported staller performance of saliva in COVID-19 diagnosis especially in terms of specificity and sensitivity. The sensitivity and specificity of the saliva sample RT-PCR were 84.2% (95% CI 60.4%–96.6%), and 98.9% (95% CI 96.1%–99.9%), respectively. In fact, countries like South Korea, Germany, and Japan successfully adapted the technology for saliva-based diagnosis. Although there are many claims made in the literature for the justification of saliva-based COVID-19 testing, we take this opportunity to address some intricacies associated with this proposition. It is quite conceivable that samples from representative areas have fewer chances of false-negative or false-positive results. Thus, for all respiratory tract infections, only a nasopharyngeal swab has been preferred to date. By virtue of abundant angiotensin- converting enzyme 2 (ACE2) receptors, the respiratory tract is the most commonly affected site and regarded as the representative area for COVID-19. ACE2 expression, as well as expression of TMPRSS2 and furin, were detected in oral mucosa using immunohistochemistry and western blot. However, these methodologies are insufficient to claim the presence or quantification of this protein on tissues of the oral mucosa. The more authentic and sensitive methodology would be flow cytometry and mass cytometry (CyTOF). Till then, viruses in saliva could be just a contamination from the respiratory source and hence future studies are recommended so that justification for the development of salivary diagnostic can be put forth. Thick saliva needs additional processing to reduce the viscosity (e.g. homogenization), which can increase cross-contamination as well as reduce the sensitivity of the test. It is well known that saliva exhibits age-dependent inter-individual-based variability in its consistency. As compared to young individuals, old individuals have thick and ropy saliva, which is attributed to the reduced functioning of salivary glands. Moreover, drug-induced xerostomia and certain xerostomia-associated systemic conditions such as dehydration, sialadenosis, sialadenitis, Sjogren's syndrome, etc. also produce saliva with similar consistency. With these aforementioned aspects in mind, we strongly believe that the saliva-based diagnostic methodology needs two different types of standardization in tune with the consistency of saliva. This involves additional technical expertise for additional intermediate steps required for identification of viscosity and homogenization of saliva samples that will have adverse cost implications. Although per test rise in the expenses will be nominal but we speculate that nationwide testing on population certainly cause a significant financial burden on low- and middle-income countries. We also recommend studies on cost impact analysis of both the testing methodologies for envisaging the practicality in population use. The timing of sample collection is a crucial factor in salivary diagnostics. Collection of saliva samples after smoking, tobacco or quid chewing (a common practice in Asian countries), tooth brushing or mouthwash use, eating food, etc. can potentially affect the inhibition of nucleic acid amplification and also cause degradation of RNA leading to false negativity. This is also applicable for saliva-based antibody testing for SARS-CoV-2 infection. Hence, it is imperative to formulate appropriate guidelines for sample collection such as avoidance of eating or drinking 1 ​hour before sample collection. However, in ‘the self-collection of sample’ strategy, which is one of the prime advantages over nasopharyngeal swabs, judicious following up of these guidelines would be questionable jeopardising the test results (false negative). The exploitation of this limitation for deliberately obtaining negative results (e.g. for air travel, work, etc.) will be disastrous. It has been proposed that nasopharyngeal swab testing could detect historical cases, while saliva might be preferable for gauging active cases. On somewhat similar lines, it is observed that asymptomatic cases are associated with high sensitivity for saliva samples as compared to nasopharyngeal swabs., Intriguingly, a contrasting trend was observed in symptomatic cases wherein sensitivity was high in nasopharyngeal swabs.9, 10, 11, 12 The proposition put forth judicious use of both techniques for decreasing the incidences of false-negative results. Hence, it is recommended that future studies should report the clinical status of the patients. In conclusion, saliva has been regarded as a potentially reliable and advantageous tool for the diagnosis of COVID-19 infection. Although, it might be true but there is a dire need to understand the compositional diversity of saliva and its possible impact on the sensitivity of the results. There is also a need to investigate the burden of technical expertise and financial investment in salivary diagnostics.

Funding source

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

All the authors associated with present manuscript declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
  12 in total

1.  RT-PCR Screening Tests for SARS-CoV-2 with Saliva Samples in Asymptomatic People: Strategy to Maintain Social and Economic Activities while Reducing the Risk of Spreading the Virus.

Authors:  Junna Oba; Hiroaki Taniguchi; Masae Sato; Reika Takamatsu; Satoru Morikawa; Taneaki Nakagawa; Hiromasa Takaishi; Hideyuki Saya; Koichi Matsuo; Hiroshi Nishihara
Journal:  Keio J Med       Date:  2021-03-19

2.  Mass Screening of Asymptomatic Persons for Severe Acute Respiratory Syndrome Coronavirus 2 Using Saliva.

Authors:  Isao Yokota; Peter Y Shane; Kazufumi Okada; Yoko Unoki; Yichi Yang; Tasuku Inao; Kentaro Sakamaki; Sumio Iwasaki; Kasumi Hayasaka; Junichi Sugita; Mutsumi Nishida; Shinichi Fujisawa; Takanori Teshima
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

3.  Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva.

Authors:  Sumio Iwasaki; Shinichi Fujisawa; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Tatsuya Fukumoto; Kaori Sato; Satoshi Oguri; Keisuke Taki; Hajime Senjo; Junichi Sugita; Kasumi Hayasaka; Satoshi Konno; Mutsumi Nishida; Takanori Teshima
Journal:  J Infect       Date:  2020-06-04       Impact factor: 6.072

4.  Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study.

Authors:  E Pasomsub; S P Watcharananan; K Boonyawat; P Janchompoo; G Wongtabtim; W Suksuwan; S Sungkanuparph; A Phuphuakrat
Journal:  Clin Microbiol Infect       Date:  2020-05-15       Impact factor: 8.067

5.  Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity.

Authors:  Wakako Sakaguchi; Nobuhisa Kubota; Tomoko Shimizu; Juri Saruta; Shinya Fuchida; Akira Kawata; Yuko Yamamoto; Masahiro Sugimoto; Mayumi Yakeishi; Keiichi Tsukinoki
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

6.  The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis.

Authors:  Mayara Lisboa Bastos; Sara Perlman-Arrow; Dick Menzies; Jonathon R Campbell
Journal:  Ann Intern Med       Date:  2021-01-12       Impact factor: 25.391

7.  Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients.

Authors:  Marie L Landry; Jody Criscuolo; David R Peaper
Journal:  J Clin Virol       Date:  2020-07-31       Impact factor: 3.168

8.  Comparing Nasopharyngeal Swab and Early Morning Saliva for the Identification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Mohan Rao; Fairuz A Rashid; Fashihah S A H Sabri; Nur Nadia Jamil; Rozainanee Zain; Rohaidah Hashim; Fairuz Amran; Huey Tean Kok; Md Anuar Abd Samad; Norazah Ahmad
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

9.  Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection.

Authors:  Sara Nunes Vaz; Daniele Souza de Santana; Eduardo Martins Netto; Celia Pedroso; Wei-Kung Wang; Felice Deminco Alves Santos; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2020-08-31       Impact factor: 3.257

10.  Clinical status determines the efficacy of salivary and nasopharyngeal samples for detection of SARS-CoV-2.

Authors:  Gargi S Sarode; Sachin C Sarode; Namrata Sengupta; Amol R Gadbail; Shailesh Gondivkar; Nilesh Kumar Sharma; Shankargouda Patil
Journal:  Clin Oral Investig       Date:  2020-10-12       Impact factor: 3.573

View more
  1 in total

Review 1.  Role of Saliva as a Non-Invasive Diagnostic Method for Detection of COVID-19.

Authors:  Supratim Ghosh; Akshay Dhobley; Kishan K Avula; Shali Joseph; Neelam Gavali; Shradha Sinha
Journal:  Cureus       Date:  2022-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.